Matinas BioPharma Holdings, Inc.: Business Overview, Financials & Competitive Analysis
Matinas BioPharma Holdings, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Platform technology with differentiated delivery mechanism addresses high-unmet-need infections, but success depends on Phase III trial outcomes and regulatory approval pathways. Early-stage biopharmaceutical with promising technology platform and clinical progress in anti-infectives (MAT2203 Phase III trials), but as a clinical-stage company lacks revenue and faces typical biotech development.
What is Matinas BioPharma Holdings, Inc.'s industry? Matinas BioPharma Holdings, Inc. (matinasbiopharma.com) operates in Biopharmaceutical - Clinical Stage / Drug Delivery. AskCyborg classifies Matinas BioPharma Holdings, Inc. under Biopharmaceutical - Clinical Stage / Drug Delivery in its company registry.
Matinas BioPharma is a clinical-stage biopharmaceutical company that identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's lead candidate MAT2203 is an or...
Cyborg Score thesis
Platform technology with differentiated delivery mechanism addresses high-unmet-need infections, but success depends on Phase III...
Read the full analyst-debate transcript →Get the Latest Matinas BioPharma Holdings, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMatinas BioPharma Holdings, Inc. Overview
Pro stress-test →Matinas BioPharma is a clinical-stage biopharmaceutical company that identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's lead candidate MAT2203 is an orally administered formulation of amphotericin B, a broad spectrum fungicidal agent, positioned to potentially replace more invasive administration methods.
Strategic Profile
Pro stress-test →Matinas is focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The company's focus on anti-infectives underscores its commitment to addressing areas of high unmet medical need and harnessing its expertise in reformulating established therapeutic agents for enhanced patient outcomes.
Competitive Landscape
Pro stress-test →Matinas competes in the clinical-stage anti-infective and drug delivery space against established pharmaceutical companies and other biotech firms developing novel infectious disease treatments. The company's differentiated LNC platform for oral delivery of traditional IV-only drugs provides a competitive edge in unmet needs for invasive fungal infections and multidrug-resistant bacteria.
Industry Context
Matinas BioPharma Holdings, Inc. operates in Biopharmaceutical - Clinical Stage / Drug Delivery.
Key facts
Founded: 2013 · Headquarters: Bedminster, New Jersey, US